INSM vs GMAB
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
INSM · Insmed$114.41 ▲ 5.19%
GMAB · Genmab$53.63 ▲ 1.69%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- INSM -40.4%
- GMAB +84.5%
Head to head
| Metric | INSM | GMAB |
|---|---|---|
| Price | $114.41 | $53.63 |
| Change today | ▲ 5.19% | ▲ 1.69% |
| Market cap | $25.10B | $33.47B |
| Return, 3 months | -15.1% | +73.7% |
| Return, year to date | -34.3% | +74.1% |
| Return, 1 year | -39.7% | +87.1% |
| P/E (TTM) | – | 45.8 |
| P/B | 34.6 | 5.3 |
| P/E percentile vs own 5y | 0th | 84th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +268.4% | +16.1% |
| Net profit growth (YoY) | +72.9% | -14.7% |
| Gross margin | 84.4% | 92.7% |
| Operating margin | -41.7% | 30.6% |
| Net margin | -39.9% | 17.0% |
| Return on equity | -72.5% | 12.1% |
| Analyst target vs. price | +66.3% | +20.7% |
| Analyst buy share | 94% | 89% |
| RSI (14) | 61 | 71 |
| 30-day volatility | 59.8% | 86.7% |
| Max drawdown, 1 year | -56.5% | -32.5% |
| Trend read | Leaning bullish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GMAB is the largest of the group by market value.
- GMAB has returned the most over the past year.
- INSM is growing revenue fastest.
- GMAB keeps the most profit per dollar of sales.
- INSM has been the calmest stock over the last 30 days.